Anika Therapeutics vs Butterfly Network
Anika Therapeutics is the larger business, with $113m of revenue in fiscal 2025 against $97.6m for Butterfly Network (1.2 times as much). Butterfly Network grew faster (19.0% against -5.9%). Anika Therapeutics kept more of each dollar of sales as profit: a net margin of -9.6% against -79.0%. Anika Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Anika TherapeuticsANIK, 2025 | Butterfly NetworkBFLY, 2025 |
|---|---|---|
| Revenue | $113m | $97.6m |
| Revenue growth | -5.9% | 19.0% |
| Net income | −$10.9m | −$77.1m |
| Operating margin | -9.8% | -88.5% |
| Net margin | -9.6% | -79.0% |
| Return on equity | -7.3% | -42.2% |
| Free cash flow | $4.4m | −$16.0m |
| Cash | $57.5m | $150m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $9.5m | — |
| Employees | 235 | 220 |
| Market value | $261m | $1.69bn |
| Price vs our value range | — | — |
| Moat score | 53 (Moderate) | 18 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 9 buys, 76 sales |